Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.11 (0.10%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
COMMENT
COMMENT
December 22, 2015

Gilead Sciences (GILD-Q) or Celgene (CELG-Q)? From an earnings forecast revision standpoint, Gilead is going up while Celgene is going down, so if you had to pick between the 2 on an earnings revision basis, you definitely have more tailwind with Gilead. They both have good pipelines, both good companies.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 22, 2015

Gilead Sciences (GILD-Q) or Celgene (CELG-Q)? From an earnings forecast revision standpoint, Gilead is going up while Celgene is going down, so if you had to pick between the 2 on an earnings revision basis, you definitely have more tailwind with Gilead. They both have good pipelines, both good companies.

BUY
BUY
October 13, 2015

His outlook over the next year is very positive. It is sitting at reasonable multiples now. There are real prospects for it to diversify away from and become more than a one-drug company. There is a chance for dividend increases and a share buyback. This space has been really hit hard, and it is hard to see that being sustained. Looks extremely attractive at this valuation level.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 13, 2015

His outlook over the next year is very positive. It is sitting at reasonable multiples now. There are real prospects for it to diversify away from and become more than a one-drug company. There is a chance for dividend increases and a share buyback. This space has been really hit hard, and it is hard to see that being sustained. Looks extremely attractive at this valuation level.

TOP PICK
TOP PICK
September 17, 2015

This is a giant pharmaceutical name, mainly in the cancer and other severe immune inflammatory condition therapies. They contain a very strong growth prospect that will benefit from aging demographics. Their therapy pipeline is extremely robust. There has been a lot of concern that 60% of their revenues comes from one drug, but that is going to be diversified as more drugs come online. They have made some acquisitions in the past. Trading at 23X forward earnings with a 25% long-term growth rate.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 17, 2015

This is a giant pharmaceutical name, mainly in the cancer and other severe immune inflammatory condition therapies. They contain a very strong growth prospect that will benefit from aging demographics. Their therapy pipeline is extremely robust. There has been a lot of concern that 60% of their revenues comes from one drug, but that is going to be diversified as more drugs come online. They have made some acquisitions in the past. Trading at 23X forward earnings with a 25% long-term growth rate.

TOP PICK
TOP PICK
September 14, 2015

They have 17 consecutive years of record revenues. Fighting blood born cancers. It is a targeted approach. He expects over 20% growth next year. It had a pull back so he is buying it.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 14, 2015

They have 17 consecutive years of record revenues. Fighting blood born cancers. It is a targeted approach. He expects over 20% growth next year. It had a pull back so he is buying it.

DON'T BUY
DON'T BUY
June 16, 2015

Trading at about 40X earnings. They have a couple of very good drugs, but have front ended drugs, with one drug representing about 65% of their total revenue.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 16, 2015

Trading at about 40X earnings. They have a couple of very good drugs, but have front ended drugs, with one drug representing about 65% of their total revenue.

Gordon Reid

Unlock Ratings

Price
$111.110
Owned
Unknown
HOLD
HOLD
May 21, 2015

A lot of large biotech names have been kind of flat lining lately. The biotech sector has taken off quite a bit, and there are some rumblings that it is a bubbling area or expensive. He would disagree with that. They are rather cheap in terms of their PE relative to their growth ratios. He likes these areas. The long-term growth expectations are still very strong.

Show full opinionHide full opinion

A lot of large biotech names have been kind of flat lining lately. The biotech sector has taken off quite a bit, and there are some rumblings that it is a bubbling area or expensive. He would disagree with that. They are rather cheap in terms of their PE relative to their growth ratios. He likes these areas. The long-term growth expectations are still very strong.

COMMENT
COMMENT
April 1, 2015

This is involved in cancer drugs. He has taken a very small position in this name because in the biotechnology sector there is a risk of approvals. Be cautious if going into this one.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 1, 2015

This is involved in cancer drugs. He has taken a very small position in this name because in the biotechnology sector there is a risk of approvals. Be cautious if going into this one.

HOLD
HOLD
September 11, 2014

Celgene (CELG-Q) or Gilead Sciences (GILD-Q)? If he had to choose one, it would be Gilead because it trades at a better valuation. Not that Celgene is trading at a bad valuation, trading at a .86 PEG ratio versus .5 for Gilead. He likes both names.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 11, 2014

Celgene (CELG-Q) or Gilead Sciences (GILD-Q)? If he had to choose one, it would be Gilead because it trades at a better valuation. Not that Celgene is trading at a bad valuation, trading at a .86 PEG ratio versus .5 for Gilead. He likes both names.

Stan Wong

Unlock Ratings

Price
$91.960
Owned
Unknown
HOLD
HOLD
June 24, 2014

Large cap biotechs are unfairly mispriced. 0.8 Peg ratio so it is cheaper than 95% of the S&P right now. You have to hang on for the ride.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 24, 2014

Large cap biotechs are unfairly mispriced. 0.8 Peg ratio so it is cheaper than 95% of the S&P right now. You have to hang on for the ride.

BUY WEAKNESS
BUY WEAKNESS
April 9, 2014

Bio tech stocks were beaten up. Buying some. Thinks they will continue to have the growth. Use stop losses.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 9, 2014

Bio tech stocks were beaten up. Buying some. Thinks they will continue to have the growth. Use stop losses.

COMMENT
COMMENT
February 13, 2014

Likes this although he sold his holdings for profits 2 months ago. Still lots of room to go on this. They are more involved in the cancer type of area. (See Top Picks.)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
February 13, 2014

Likes this although he sold his holdings for profits 2 months ago. Still lots of room to go on this. They are more involved in the cancer type of area. (See Top Picks.)

PAST TOP PICK
PAST TOP PICK
March 14, 2013

(A Top Pick April 19/12. Up 45.33%.) Cancer drug producer. Sold his holdings at about $100 last month. Still likes but would wait for it to come down a bit before buying. Great long-term growth at 20%-25%. Trades at about 20X PE.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 14, 2013

(A Top Pick April 19/12. Up 45.33%.) Cancer drug producer. Sold his holdings at about $100 last month. Still likes but would wait for it to come down a bit before buying. Great long-term growth at 20%-25%. Trades at about 20X PE.

TOP PICK
TOP PICK
April 19, 2012
Biopharmaceutical company. Strong grower. One of the few biotech companies that is making money and growing strong margins. Margins are growing at 20%-25% long-term growth. Trading at 16X.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 19, 2012
Biopharmaceutical company. Strong grower. One of the few biotech companies that is making money and growing strong margins. Margins are growing at 20%-25% long-term growth. Trading at 16X.
TOP PICK
TOP PICK
March 8, 2012
Blood cancer drug. About 55%-70% of their revenue. Interesting pipeline, though. Very strong block buster drug.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 8, 2012
Blood cancer drug. About 55%-70% of their revenue. Interesting pipeline, though. Very strong block buster drug.
SELL
SELL
January 17, 2012
Has done very, very well. Stock price is skyrocketing. Have a lot of debt. Thinks insiders have been selling. BV of around $45 is reasonable. If he owned, he would be looking to get out.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 17, 2012
Has done very, very well. Stock price is skyrocketing. Have a lot of debt. Thinks insiders have been selling. BV of around $45 is reasonable. If he owned, he would be looking to get out.
Showing 76 to 90 of 90 entries